Keytruda (pembrolizumab) — Filing acceptance
H2 2026
FDA set Prescription Drug User Fee Act (PDUFA) dates in the second half of 2026 for these applications.Source filing
MRK biotech catalysts & pipeline
MERCK & CO INC · Data as of 2026-10-25
Upcoming catalysts
sacituzumab tirumotecan — Conference presentation
Oct 23–Oct 27
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27.Source filing
Keytruda (pembrolizumab) — Conference presentation
Oct 26
The Company will hold an Oncology Investor Event to coincide with the European Society for Medical Oncology Congress 2026 on Monday, Oct. 26, 2026, at 6 p.m. CET / 1 p.m. EDT, during which senior management will provide an update on the Company's oncology strategy and program.Source filing